REXAHN Pharmaceuticals Reviews

0 Reviews
Recommend to a friend
Approve of CEO
REXAHN Pharmaceuticals Chairman and CEO Chang H. Ahn
Chang H. Ahn
0 Ratings

REXAHN Pharmaceuticals Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Headquarters Rockville, MD
Size 16 to 50 Employees
Founded Unknown
Type Company - Public (RNN)
Industry Biotech & Pharmaceuticals
Revenue $1 to $5 million (USD) per year
Competitors Pfizer, GlaxoSmithKline, Roche

Rexahn Pharmaceuticals has its R&D sights set on difficult-to-treat cancers and central nervous system (CNS) disorders. A biopharmaceutical company, Rexahn has three drug candidates in clinical stages of development, including its lead candidate and pancreatic cancer treatment Archexin (designed to inhibit a protein involved in cancer cell proliferation); Serdaxin, a depression and Parkinson's disease drug; and Zoraxel, a treatment for erectile dysfunction. The company also has seven cancer drugs in preclinical development. It develops its candidates through its own R&D... More

Work at REXAHN Pharmaceuticals? Share Your Experiences

REXAHN Pharmaceuticals

Click to Rate